SEC Comment Letter 0000000000-24-001460 to Sunshine Biopharma Inc. (SBFM)
Sunshine Biopharma Inc.
Date: Feb. 6, 2024 · CIK: 0001402328 · Accession: 0000000000-24-001460
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276817
Letter
United States securities and exchange commission logo February 6, 2024 Steve Slilaty, Ph.D. Chief Executive Officer Sunshine Biopharma, Inc. 1177 Avenue of the Americas, 5th Floor New York, NY 10036 Re:Sunshine Biopharma, Inc. Registration Statement on Form S-1 Filed February 1, 2024 File No. 333-276817 Dear Steve Slilaty: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeff Cahlon, Esq.
Show Raw Text
United States securities and exchange commission logo
February 6, 2024
Steve Slilaty, Ph.D.
Chief Executive Officer
Sunshine Biopharma, Inc.
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Re:Sunshine Biopharma, Inc.
Registration Statement on Form S-1
Filed February 1, 2024
File No. 333-276817
Dear Steve Slilaty:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeff Cahlon, Esq.